Meta‐analysis results have shown that rhuIL‐2 immunoadjuvant therapy is safe for PTB/MDR‐TB patients and can promote the proliferation and transformation of CD4+ T cells and NK cells, leading to an increased sputum smear conversion rate in PTB/MDR‐TB patients. This evidence concerns the gene CD4 and tuberculosis.